<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Diversity</title>
	<atom:link href="http://www.tapanray.in/tag/diversity/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Indian Drug Industry’s Looming Talent Crisis &#8211; A Recent Landscape</title>
		<link>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape</link>
		<comments>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/#comments</comments>
		<pubDate>Thu, 18 Jul 2024 07:41:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[academia]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[great]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-skilling]]></category>
		<category><![CDATA[resignation]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[up-skilling]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10869</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry, a global generics and drug manufacturing powerhouse, is facing a critical talent deficit. The shortage of skilled professionals is impeding innovation, drug development, and the industry&#8217;s overall competitiveness. This challenge, exacerbated by recent industry dynamics, demands immediate &#8230; <a href="http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why D&amp;I Is A Powerful Growth Driver For Pharma Industry</title>
		<link>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-di-is-a-powerful-growth-driver-for-pharma-industry</link>
		<comments>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/#comments</comments>
		<pubDate>Mon, 10 Jun 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[empathetic]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[facets]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9578</guid>
		<description><![CDATA[‘Diverse India’ now needs an ‘inclusive society’, vowed the Prime Minister of India, after his massive electoral win on May 23, 2019. Many may consider a part of it as rhetoric, notwithstanding, as and when the government policy of Diversity and Inclusion &#8230; <a href="http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Diversity And Inclusion’: A Missing Link For Indian Pharma</title>
		<link>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=diversity-and-inclusion-a-missing-link-for-indian-pharma</link>
		<comments>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/#comments</comments>
		<pubDate>Mon, 25 Jun 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[oriented]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9015</guid>
		<description><![CDATA[Inadequate access to affordable health care to a vast majority of the population has been a favorite topic of debate, since long, globally. This discourse is generally centered around the least developed and the developing world, such as India. However, &#8230; <a href="http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
